Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 286 results for "ranbaxy"

Withdraw nod for 28 drug applications of Ranbaxy: Sun Pharma to USFDA
Livemint.com

Sun Pharma unit asks US FDA to withdraw nod for 28 drug applic...

In a BSE filing, Sun Pharmaceutical Industries said: One of the company's wholly-owned subsidiaries has voluntarily requested the USFDA to withdraw approval for 28 Abbreviated New Drug Applications (ANDAs). It further said: These old Money Today, 3 weeks ago
[x]  

26 images for ranbaxy

Financial Express, 6 days ago
Money Control, 3 weeks ago
Livemint.com, 3 weeks ago
Uranium Investing News, 1 month ago
Brief Report.co.uk, 1 month ago
Yahoo! Finance, 1 month ago
FiercePharma, 1 month ago
Yahoo! Finance, 1 month ago
4 Traders, 1 month ago
Reuters UK, 1 month ago

Ranbaxy portfolio makes up for 37% of Sun's India sales

Ranbaxy contributes a little lower than Rs 3k cr to the India sales of the merged entity
 Business Standard3 weeks ago

Daiichi case: Delhi HC to hear main arguments in March

NEW DELHI: The Delhi High Court will hear the main arguments in Daiichi Sankyo's case against former Ranbaxy promoters Malvinder and Shivinder Singh in March 2017. This includes the Singh brothers arguments challenging the Japanese drug maker's ...
 Economic Times1 month ago Former Ranbaxy promoter Shivinder Singh to submit asset declarations to Delhi HC within three days  Business Standard1 month ago

Sun Pharma requests USFDA to withdraw 28 product approvals given to Ranbaxy

Drugmaker Sun Pharmaceutical Industries has voluntarily requested the United States Food and Drug Administration to withdraw approvals given to 28 Abbreviated New Drug Applications (ANDAs). These older drug products belong to erstwhile Ranbaxy Laboratories ...
 Business Line3 weeks ago
Uranium Investing News

Ranbaxy and AstraZeneca Prevail in Nexium® Pay-For-Delay Case

, the U.S. Court of Appeals for the First Circuit upheld a 2014 jury verdict for AstraZeneca (AZ) and Ranbaxy regarding a 2012 payment of $700 million from AstraZeneca for Ranbaxy to abandon its challenge to patents covering Nexium®. Importantly, ...
 JD Supra1 month ago Landmark Court Decision Upheld for Pharmaceutical Industry  Uranium Investing News1 month ago AstraZeneca, Ranbaxy prevail in landmark pay-for-delay case  FiercePharma1 month ago ASTRAZENECA : U.S. court upholds AstraZeneca, Ranbaxy win in Nexium antitrust trial  4 Traders1 month ago
[x]  
Yahoo! Finance

AstraZeneca Plc (NYSE:AZN), Ranbaxy Laboratories Limited (NYSE:RBXLY) Wins Over Illegal Deal Case

The 1st US Circuit Court of Appeals has recently ruled in favor of AstraZeneca Plc (NYSE:AZN) and Ranbaxy Laboratories Limited (NYSE:RBXLY) on a long-lasting class action lawsuit involving an illegal agreement between the two companies related to ...
 4 Traders1 month ago AstraZeneca PLC (ADR) (AZN), Ranbaxy Laboratories Limited (ADR) (RBXLY) Wins Over Illegal Deal Case  InsiderMonkey.com1 month ago

Finasteride Market: Industry Analysis Report, Regional Outlook, Application Development Potential & Forecast, 2016 2024.

"Finasteride market share comprises of Merck Sharp & Dohme, Sun Pharmaceuticals, Ranbaxy Laboratories, Dr. Reddys Laboratories and Intas Pharmaceuticals, Teva Pharmaceuticals, Actavis, Hetero Labs, Yabao Pharmaceuticals, Cipla, Yangtze River Pharma, ...
 Digital Journal1 month ago

FiercePharmaAsia: Takeda, Valeant and more

Welcome to this week's FiercePharmaAsia report. Takeda announced two dealsat the J.P. Morgan Healthcare Conference—a $5.2 billion proposal to acquire Ariad and another one of $125 million to collaborate with Maverick on T-cell R&D. Valeant , in an ...
 FiercePharma2 days ago

Trump's comments on drug prices sink pharma stocks; Teva lowers guidance by $ 1 billion

View: 430 The New Year began with the JP Morgan Healthcare Conference— the drug industry's annual investor meet — where industry leaders were busy announcing deals, until Donald Trump accused the industry of getting away with murder. His ...
 PharmaCompass3 days ago
Pharmaceutical Tech.com

Daiichi Sankyo shuts India R&D division

Japanese drug maker Daiichi Sankyo has shut down its India research division as part of the company's overall strategy to increase R&D productivity as the company narrows down its focus to cancer research. The Daiichi Sankyo India Pharma Limited ...
 Pharmaceutical Tech.com3 days ago Daiichi shuts India R&D division  Economic Times4 days ago Daiichi Sankyo to Shutter Indian R&D Center, 170 Employees Affected  Pharma Live4 days ago Daiichi Sankyo says Sayonara to India; terminates contract of 170 employees  Smart Investor4 days ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less